Promising Mid Cap Stocks To Follow Now - July 23rd

Oklo, Marathon Digital, and Abivax are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid cap stocks refer to shares of companies whose market capitalization generally falls between about $2 billion and $10 billion. These firms are more established and stable than small-cap companies but often have greater growth potential than large-cap corporations. As a result, mid cap stocks attract investors seeking a balance of moderate risk and growth opportunity. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

Oklo (OKLO)

Oklo Inc. designs and develops fission power plants to provide reliable and commercial-scale energy to customers in the United States. It also provides used nuclear fuel recycling services. The company was founded in 2013 and is based in Santa Clara, California.

Shares of Oklo stock traded up $5.37 during trading hours on Wednesday, reaching $66.69. The company had a trading volume of 31,477,809 shares, compared to its average volume of 15,173,985. The firm has a market cap of $9.31 billion, a PE ratio of -12.33 and a beta of 0.57. Oklo has a one year low of $5.35 and a one year high of $73.55. The business has a fifty day simple moving average of $53.01 and a 200 day simple moving average of $38.40.

Read Our Latest Research Report on OKLO

Marathon Digital (MARA)

Shares of MARA traded down $2.38 during mid-day trading on Wednesday, reaching $17.51. The company had a trading volume of 119,529,791 shares, compared to its average volume of 42,437,000. The company has a market capitalization of $6.16 billion, a price-to-earnings ratio of -12.03 and a beta of 6.53. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.79 and a current ratio of 0.79. The firm has a 50-day moving average price of $16.32 and a 200 day moving average price of $15.42. Marathon Digital has a 52 week low of $9.81 and a 52 week high of $30.28.

Read Our Latest Research Report on MARA

Abivax (ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Shares of Abivax stock traded up $59.40 during trading on Wednesday, reaching $69.40. 25,889,695 shares of the stock traded hands, compared to its average volume of 324,656. Abivax has a 52-week low of $4.77 and a 52-week high of $71.00. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. The business has a fifty day simple moving average of $7.14 and a two-hundred day simple moving average of $6.80.

Read Our Latest Research Report on ABVX